Clinical significance and potential role of trimethylamine N-oxide in neurological and neuropsychiatric disorders. Issue 11 (November 2022)
- Record Type:
- Journal Article
- Title:
- Clinical significance and potential role of trimethylamine N-oxide in neurological and neuropsychiatric disorders. Issue 11 (November 2022)
- Main Title:
- Clinical significance and potential role of trimethylamine N-oxide in neurological and neuropsychiatric disorders
- Authors:
- Mudimela, Sowjanya
Vishwanath, Narahari Koppa
Pillai, Anilkumar
Morales, Rodrigo
Marrelli, Sean P.
Barichello, Tatiana
Giridharan, Vijayasree V. - Abstract:
- Highlights: Trimethylamine N-oxide (TMAO) is a major gut metabolite from dietary phosphatidylcholine. TMAO levels impact oxidative stress, microglial activation, and the apoptosis of neurons. TMAO levels are associated with increased risk of first stroke. TMAO can have neuroprotective or neurodegenerative activities in different conditions. Abstract: In the past three decades, research on the gut microbiome and its metabolites, such as trimethylamines (TMA), trimethylamine N-oxide (TMAO), short-chain fatty acids (SCFAs), branched-chain amino acids (BCAAs), bile acids, tryptophan and indole derivatives, has attracted the attention of many scientists and industrialists. Among these metabolites, TMAO is produced from dietary choline, phosphatidylcholine, carnitine, and betaine. TMAO and other gut metabolites, such as TMA and SCFAs, reach the brain by crossing the blood–brain barrier (BBB) and are involved in brain development, neurogenesis, and behavior. Gut-microbiota composition is influenced by diet, lifestyle, antibiotics, and age. Several studies have confirmed that altered TMAO levels contribute to metabolic, vascular, psychiatric, and neurodegenerative disorders. This review focuses on how altered TMAO levels impact oxidative stress, microglial activation, and the apoptosis of neurons, and may lead to neuroinflammation, which can subsequently result in the development of psychiatric, cognitive, and behavioral disorders.
- Is Part Of:
- Drug discovery today. Volume 27:Issue 11(2022)
- Journal:
- Drug discovery today
- Issue:
- Volume 27:Issue 11(2022)
- Issue Display:
- Volume 27, Issue 11 (2022)
- Year:
- 2022
- Volume:
- 27
- Issue:
- 11
- Issue Sort Value:
- 2022-0027-0011-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-11
- Subjects:
- Trimethylamine oxide -- Gut microbiome -- Neurological disorder -- Neuropsychiatric disorder
Drugs -- Design -- Periodicals
Drugs -- Research -- Periodicals
615.1 - Journal URLs:
- http://www.sciencedirect.com/science/journal/13596446 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.drudis.2022.08.002 ↗
- Languages:
- English
- ISSNs:
- 1359-6446
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3629.120500
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 24141.xml